Enavate Sciences GP
$345M 13F equity value
7 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Enavate Sciences GP covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| SION | SIONNA THERAPEUTICS INC | 2,478,030 | $109M | 31.6% |
| ZBIO | ZENAS BIOPHARMA INC | 3,919,159 | $99M | 28.8% |
| IMNM | IMMUNOME INC | 3,613,799 | $77M | 22.2% |
| BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | 2,626,946 | $20M | 5.8% |
| CMPX | COMPASS THERAPEUTICS INC | 7,788,150 | $17M | 4.9% |
| UPB | UPSTREAM BIO INC | 2,459,703 | $17M | 4.9% |
| CAMP | CAMP4 THERAPEUTICS CORP | 1,425,541 | $6M | 1.8% |
Track Enavate Sciences GP's 13F portfolio: $345M in reported holdings, 7 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}